Nanospectra Biosciences raises funds for ablation therapy products

Nanospectra’s flagship product AuroLase is the ‘first and only’ ultra-focal ablation therapy for prostate cancer. Credit: Jennifer Gordetsky and Jonathan Epstein.



  • Nanospectra